Diamedica Therapeutics News - DMA

DiaMedica Meets Primary Endpoint from Phase II DM-83 Study in Type 2 Diabetes

WINNIPEG, MANITOBA--(Marketwire - July 14, 2008) - DiaMedica Inc. (TSX VENTURE:DMA) ("DiaMedica"), a drug discovery and development company...

DiaMedica Meets Primary Endpoint from Phase II DM-83 Study in Type 2 Diabetes

WINNIPEG, MANITOBA ("DiaMedica"), a drug discovery and development company focused on novel treatments for Type 2 diabetes, today announces...

DiaMedica is to Raise Approximately $2.0 Million

WINNIPEG, MANITOBA--(Marketwire - June 24, 2008) - DiaMedica Inc. (TSX VENTURE:DMA) ("DiaMedica" or the "Company"), a drug discovery and...

DiaMedica is to Raise Approximately $2.0 Million

WINNIPEG, MANITOBA ("DiaMedica" or the "Company"), a drug discovery and development company focused on novel treatments for Type 2 diabetes...

DiaMedica Announces Last Patient Out for DM-83 Phase II Human Clinical Trial

WINNIPEG, MANITOBA--(Marketwire - May 26, 2008) - DiaMedica Inc. (TSX VENTURE:DMA), a drug discovery and development company focused on novel...

DiaMedica Announces Last Patient Out for DM-83 Phase II Human Clinical Trial

WINNIPEG, MANITOBA , a drug discovery and development company focused on novel treatments for Type 2 diabetes, today announces last patient out in...

DiaMedica Receives pre-IND FDA Guidance on DM-71

WINNIPEG, MANITOBA--(Marketwire - May 14, 2008) - DiaMedica Inc. (TSX VENTURE:DMA), a drug discovery and development company focused on novel...

DiaMedica Receives pre-IND FDA Guidance on DM-71

WINNIPEG, MANITOBA , a drug discovery and development company focused on novel treatments for Type 2 diabetes, today announced that it has...

DiaMedica Completes Enrollment in Phase II Clinical Trial for DM-83

WINNIPEG, MANITOBA--(Marketwire - May 5, 2008) - DiaMedica Inc. (TSX VENTURE:DMA), a drug discovery and development company focused on novel...

DiaMedica Completes Enrollment in Phase II Clinical Trial for DM-83

WINNIPEG, MANITOBA , a drug discovery and development company focused on novel treatments for Type 2 diabetes, today announces that it has...

DiaMedica Announces Changes to Board of Directors and Corporate Officers

WINNIPEG, MANITOBA--(Marketwire - April 8, 2008) - DiaMedica Inc. (TSX VENTURE:DMA), a drug discovery and development company focused on novel...

DiaMedica Announces Changes to Board of Directors and Corporate Officers

WINNIPEG, MANITOBA , a drug discovery and development company focused on novel treatments for type 2 diabetes, announces today the appointment of...

DiaMedica Enrolls First Patient in Phase II Human Clinical Trial for DM-83

WINNIPEG, MANITOBA , a drug discovery and development company focused on novel treatments for type 2 diabetes, has announced that it enrolled the...

DiaMedica Receives Regulatory Clearance for Phase II Human Study of DM-99

WINNIPEG, MANITOBA , a drug discovery and development company focused on novel treatments for type 2 diabetes is pleased to announce that it has...

DM-99 Shown to Improve Glucose Metabolism in Pre-Clinical Study, DiaMedica Seeking Regulatory Clearance for Phase II Human Trial

WINNIPEG, MANITOBA , a clinical stage biotechnology company developing novel treatments for various stages of type 2 diabetes, is pleased to...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Diamedica Therapeutics (DMA)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

DMA News

DiaMedica Meets Primary Endpoint from Phase II DM-83 Study in Type 2 Diabetes

DiaMedica Meets Primary Endpoint from Phase II DM-83 Study in Type 2 Diabetes

DiaMedica is to Raise Approximately $2.0 Million

DiaMedica is to Raise Approximately $2.0 Million

DiaMedica Announces Last Patient Out for DM-83 Phase II Human Clinical Trial

DiaMedica Announces Last Patient Out for DM-83 Phase II Human Clinical Trial

DiaMedica Receives pre-IND FDA Guidance on DM-71

DiaMedica Receives pre-IND FDA Guidance on DM-71

DiaMedica Completes Enrollment in Phase II Clinical Trial for DM-83

DiaMedica Completes Enrollment in Phase II Clinical Trial for DM-83

DiaMedica Announces Changes to Board of Directors and Corporate Officers

DiaMedica Announces Changes to Board of Directors and Corporate Officers

DiaMedica Enrolls First Patient in Phase II Human Clinical Trial for DM-83

DiaMedica Receives Regulatory Clearance for Phase II Human Study of DM-99

DM-99 Shown to Improve Glucose Metabolism in Pre-Clinical Study, DiaMedica Seeking Regulatory Clearance for Phase II Human Trial

DMA Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Diamedica Therapeutics (DMA) News

Diamedica Therapeutics (DMA)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

DMA News

DiaMedica Meets Primary Endpoint from Phase II DM-83 Study in Type 2 Diabetes

DiaMedica Meets Primary Endpoint from Phase II DM-83 Study in Type 2 Diabetes

DiaMedica is to Raise Approximately $2.0 Million

DiaMedica is to Raise Approximately $2.0 Million

DiaMedica Announces Last Patient Out for DM-83 Phase II Human Clinical Trial

DiaMedica Announces Last Patient Out for DM-83 Phase II Human Clinical Trial

DiaMedica Receives pre-IND FDA Guidance on DM-71

DiaMedica Receives pre-IND FDA Guidance on DM-71

DiaMedica Completes Enrollment in Phase II Clinical Trial for DM-83

DiaMedica Completes Enrollment in Phase II Clinical Trial for DM-83

DiaMedica Announces Changes to Board of Directors and Corporate Officers

DiaMedica Announces Changes to Board of Directors and Corporate Officers

DiaMedica Enrolls First Patient in Phase II Human Clinical Trial for DM-83

DiaMedica Receives Regulatory Clearance for Phase II Human Study of DM-99

DM-99 Shown to Improve Glucose Metabolism in Pre-Clinical Study, DiaMedica Seeking Regulatory Clearance for Phase II Human Trial

DMA Discussion

Your Recent History